Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Kaisami
Page 1
Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes.
Nasiri H, Mirmazhari A, Mirzakhani L, Asgarian P, Gholibeigi A, Ghandali T, Moghaddam MT, Mohammadi M, Karimi M, Makhlough A. Nasiri H, et al. BMC Nephrol. 2025 Nov 14;26(1):638. doi: 10.1186/s12882-025-04561-x. BMC Nephrol. 2025. PMID: 41239296 Free PMC article.
Across analyses, roxadustat and daprodustat increased hemoglobin more than ESA or placebo overall. Roxadustat tended to rank highest for hemoglobin, particularly in non-dialysis populations, whereas daprodustat showed advantages among dialysis-dependent patients and was as …
Across analyses, roxadustat and daprodustat increased hemoglobin more than ESA or placebo overall. Roxadustat tended to rank highest …
An asymmetric tetrabody is a potent and efficacious agonist of the erythropoietin receptor in vitro and in vivo.
Adams JJ, Blazer LL, Chung J, Karimi M, Davidson T, Bruce HA, Singer AU, Yang N, Cardarelli L, Pot I, Colombo L, Huang LJ, Ma Y, Michnick SW, Moe OW, Sidhu SS. Adams JJ, et al. Protein Sci. 2025 Oct;34(10):e70292. doi: 10.1002/pro.70292. Protein Sci. 2025. PMID: 40960423 Free PMC article.
In a knock-in mouse model, where mouse EPOR was replaced by human EPOR, purified Tb-Fc(2) stimulated erythropoiesis with greater potency, efficacy, and duration than darbepoetin, a recombinant EPO that is the leading therapeutic erythropoiesis-stimulating agent (ESA). Coll …
In a knock-in mouse model, where mouse EPOR was replaced by human EPOR, purified Tb-Fc(2) stimulated erythropoiesis with greater potency, ef …
Erythropoiesis-stimulating agents and cardiovascular mortality: A systematic review and meta-analysis of 17 studies and 372,156 hemodialysis patients.
Karimi Z, Raeisi Shahraki H, Mohammadian-Hafshejani A. Karimi Z, et al. Int J Cardiol Cardiovasc Risk Prev. 2023 Oct 18;19:200220. doi: 10.1016/j.ijcrp.2023.200220. eCollection 2023 Dec. Int J Cardiol Cardiovasc Risk Prev. 2023. PMID: 37953767 Free PMC article. Review.
METHODS: We comprehensively searched major databases for observational and interventional studies on ESA use and cardiovascular mortality in hemodialysis patients published from 1980 to September 2023. ...Further research is warranted, particularly randomized controlled tr …
METHODS: We comprehensively searched major databases for observational and interventional studies on ESA use and cardiovascular morta …